|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer
incidence and mortality patterns in Europe: Estimates for 40
countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ljungberg B, Albiges L, Abu-Ghanem Y,
Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F,
Hora M, Kuczyk MA, et al: European association of urology
guidelines on renal cell carcinoma: The 2019 update. Eur Urol.
75:799–810. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Motzer RJ, Jonasch E, Agarwal N, Bhayani
S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman
M, et al: Kidney cancer, version 2.2017, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 15:804–834. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gore ME and Larkin JM: Challenges and
opportunities for converting renal cell carcinoma into a chronic
disease with targeted therapies. Br J Cancer. 104:399–406. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iness AN, Felthousen J, Ananthapadmanabhan
V, Sesay F, Saini S, Guiley KZ, Rubin SM, Dozmorov M and Litovchick
L: The cell cycle regulatory DREAM complex is disrupted by high
expression of oncogenic B-Myb. Oncogene. 38:1080–1092. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jia Y, Gao Y, Li J, Chang Z, Yan J and Qin
Y: Prognostic implications of MYBL2 in resected Chinese gastric
adenocarcinoma patients. Onco Targets Ther. 12:1129–1135. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen J and Chen X: MYBL2 is targeted by
miR-143-3p and regulates breast cancer cell proliferation and
apoptosis. Oncol Res. 26:913–922. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qin H, Li Y, Zhang H, Wang F, He H, Bai X
and Li S: Prognostic implications and oncogenic roles of MYBL2
protein expression in esophageal squamous-cell carcinoma. Onco
Targets Ther. 12:1917–1927. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guan Z, Cheng W, Huang D and Wei A: High
MYBL2 expression and transcription regulatory activity is
associated with poor overall survival in patients with
hepatocellular carcinoma. Curr Res Transl Med. 66:27–32. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jin Y, Zhu H, Cai W, Fan X, Wang Y, Niu Y,
Song F and Bu Y: B-Myb is up-regulated and promotes cell growth and
motility in non-small cell lung cancer. Int J Mol Sci. 18(pii):
E8602017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu R, Li C, Lin X, Chen Q, Li J, Song L,
Lin L, Liu J, Zhang Y, Kong W, et al: Clinicopathologic features
and prognostic implications of MYBL2 protein expression in
pancreatic ductal adenocarcinoma. Pathol Res Pract. 213:964–968.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Amin MB, Edge SB, Greene FL, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC Cancer Staging Manual. 8th. Springer; pp.
751–752. 2017
|
|
13
|
Wu H and Zhang J: Decreased expression of
TFAP2B in endometrial cancer predicts poor prognosis: A study based
on TCGA data. Gynecol Oncol. 149:592–597. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Team RC: R: A language and environment for
statistical computing. R foundation for statistical computing,
version 2.15.1; Vienna, Austria: 2012
|
|
15
|
Musa J, Aynaud MM, Mirabeau O, Delattre O
and Grünewald TG: MYBL2 (B-Myb): A central regulator of cell
proliferation, cell survival and differentiation involved in
tumorigenesis. Cell Death Dis. 8:e28952017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fan X, Wang Y, Jiang T, Cai W, Jin Y, Niu
Y, Zhu H and Bu Y: B-Myb mediates proliferation and migration of
non-small-cell lung cancer via suppressing IGFBP3. Int J Mol Sci.
19(pii): E14792018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Khatri P, Sirota M and Butte AJ: Ten years
of pathway analysis: Current approaches and outstanding challenges.
PLoS Comput Biol. 8:e10023752012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang Z, Tao Y, Xu X, Cai F, Yu Y and Ma L:
Bufalin inhibits cell proliferation and migration of hepatocellular
carcinoma cells via APOBEC3F induced intestinal immune network for
IgA production signaling pathway. Biochem Biophys Res Commun.
503:2124–2131. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mayor PC, Eng KH, Singel KL, Abrams SI,
Odunsi K, Moysich KB, Fuleihan R, Garabedian E, Lugar P, Ochs HD,
et al: Cancer in primary immunodeficiency diseases: Cancer
incidence in the United States immune deficiency network registry.
J Allergy Clin Immunol. 141:1028–1035. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Villarino AV, Kanno Y and O'Shea JJ:
Mechanisms and consequences of Jak-STAT signaling in the immune
system. Nat Immunol. 18:374–384. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cui C, Cheng X, Yan L, Ding H, Guan X,
Zhang W, Tian X and Hao C: Downregulation of TfR1 promotes
progression of colorectal cancer via the JAK/STAT pathway. Cancer
Manag Res. 11:6323–6341. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Toh TB, Lim JJ, Hooi L, Rashid MBMA and
Chow EK: Targeting Jak/Stat pathway as a therapeutic strategy
against SP/CD44+ tumorigenic cells in
Akt/β-catenin-driven hepatocellular carcinoma. J Hepatol.
72:104–118. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang X, Liao X, Yu T, Gong Y, Zhang L,
Huang J, Yang C, Han C, Yu L, Zhu G, et al: Analysis of clinical
significance and prospective molecular mechanism of main elements
of the JAK/STAT pathway in hepatocellular carcinoma. Int J Oncol.
55:805–822. 2019.PubMed/NCBI
|
|
25
|
Mendez Luque LF, Blackmon AL, Ramanathan G
and Fleischman AG: Key role of inflammation in myeloproliferative
neoplasms: Instigator of disease initiation, progression, and
symptoms. Curr Hematol Malig Rep. 14:145–153. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cornez I, Yajnanarayana SP, Wolf AM and
Wolf D: JAK/STAT disruption induces immuno-deficiency: Rationale
for the development of JAK inhibitors as immunosuppressive drugs.
Mol Cell Endocrinol. 451:88–96. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Welsch K, Holstein J, Laurence A and
Ghoreschi K: Targeting JAK/STAT signalling in inflammatory skin
diseases with small molecule inhibitors. Eur J Immunol.
47:1096–1107. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fischer M, Quaas M, Steiner L and Engeland
K: The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle
genes. Nucleic Acids Res. 44:164–174. 2016. View Article : Google Scholar : PubMed/NCBI
|
